POAI News and Press, Predictive Oncology Inc. From 03/21/23

2023-03-21 17:26:45 ET Predictive Oncology press release ( NASDAQ: POAI ): FY  GAAP EPS of -$0.35. Revenue of $1.51M (+6.3% Y/Y). For further details see: Predictive Oncology GAAP EPS of -$0.35, revenue of $1.51M

EAGAN, Minn., March 21, 2023 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (Nasdaq: POAI) , a science-driven company leveraging its proprietary artificial intelligence and machine learning capabilities, extensive biorepository of tumor samples, Clinical Laboratory Improvement Amendments (...

--News Direct-- Predictive Oncology chief business officer Pamela Bush and Dom Pollard, business development manager at Cancer Research Horizons, join Proactive's Natalie Stoberman to discuss their new partnership for new cancer drug development. The collaboration will utilize Predictive ...

Predictive Oncology (NASDAQ: POAI) , a science-driven company leveraging its proprietary artificial intelligence and machine learning capabilities, extensive biorepository of tumor samples, CLIA laboratory and GMP facility to accelerate oncologic drug discovery and enable drug development, i...

2023-03-17 07:29:21 ET Predictive Oncology ( NASDAQ: POAI ) is collaborating with Cancer Research Horizons (CRH) to develop cancer drugs. CRH is the innovation arm of Cancer Research UK –  one of the world's largest charitable funders of cancer research,&#...

EAGAN, Minn., March 17, 2023 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI) together with Cancer Research Horizons, the innovation engine at the core of the world’s largest private funder of cancer research, Cancer Research UK (CRUK), today announce that they have partner...

2023-03-17 06:58:02 ET Predictive Oncology's ( NASDAQ: POAI ) declared a dividend of one one-thousandth of a share of newly designated Series F Preferred Stock for each outstanding common share held of record, as of March 27. The company said the outstanding shares of ...

EAGAN, Minn., March 14, 2023 (GLOBE NEWSWIRE) -- Predictive Oncology (Nasdaq: POAI) , a science driven company leveraging its proprietary artificial intelligence and machine learning capabilities, extensive biorepository of tumor samples, CLIA laboratory and GMP facility to accelerate on...

Predictive Oncology (NASDAQ: POAI) CEO Raymond Vennare has issued a letter to shareholders, providing an overview of the company and a look at the significant progress the company has made in respect to validating its commercial platform and publishing its proof of concept. In the letter, Vennar...

Predictive Oncology (NASDAQ: POAI) CEO Raymond Vennare was a featured guest during the latest interview released by Proactive US. Vennare joined Cvergenx CEO Javier Torres-Roca to talk about the recent announcement that the two companies have joined forces to create a new genomic-based artificia...